
|Articles|June 15, 2004
Topical cyclosporine can handle more than dry-eye disease
Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways
Advertisement
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
Integrating Gene Therapy into Clinical Care for Sickle Cell Disease
2
Deevyashali Parekh, MBBS, on Evaluating CAR-T in Patients With Multiple Myeloma and Renal Failure
3
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
4
Janna Minehart, MD, on Hematology-Oncology Immunotherapy Highlights at ASH 2025
5

















































